DDInter1867 DDInter448
A phenothiazine used as an antipsychotic agent and as an antiemetic.
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.
Triflupromazine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Crizotinib
Triflupromazine {u} (Compound) downregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Triflupromazine {u} (Compound) upregulates {v} (Gene) SREBF2
SREBF2 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Triflupromazine {u} (Compound) downregulates {v} (Gene) SUV39H1
SUV39H1 {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Triflupromazine {u} (Compound) resembles {v} (Compound) Thioridazine
Thioridazine {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Triflupromazine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is associated with {v} (Disease) lung cancer
lung cancer {u} (Disease) is treated by {v} (Compound) Crizotinib
Triflupromazine {u} (Compound) downregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) interacts with {v} (Gene) MAP3K3
MAP3K3 {u} (Gene) is bound by {v} (Compound) Crizotinib
Triflupromazine {u} (Compound) upregulates {v} (Gene) SREBF2
SREBF2 {u} (Gene) regulates {v} (Gene) TNIP1
TNIP1 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Triflupromazine {u} (Compound) upregulates {v} (Gene) MVD
MVD {u} (Gene) is regulated by {v} (Gene) NSDHL
NSDHL {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Triflupromazine {u} (Compound) upregulates {v} (Gene) LDLR
LDLR {u} (Gene) regulates {v} (Gene) PTK2
PTK2 {u} (Gene) is bound by {v} (Compound) Crizotinib
Triflupromazine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Crizotinib (Compound)
Triflupromazine (Compound) downregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Crizotinib (Compound)
Triflupromazine (Compound) upregulates SREBF2 (Gene) and SREBF2 (Gene) is upregulated by Crizotinib (Compound)
Triflupromazine (Compound) downregulates SUV39H1 (Gene) and SUV39H1 (Gene) is downregulated by Crizotinib (Compound)
Triflupromazine (Compound) resembles Thioridazine (Compound) and Thioridazine may lead to a major life threatening interaction when taken with Crizotinib
Triflupromazine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is associated with lung cancer (Disease) and lung cancer (Disease) is treated by Crizotinib (Compound)
Triflupromazine (Compound) downregulates NFKBIA (Gene) and NFKBIA (Gene) interacts with MAP3K3 (Gene) and MAP3K3 (Gene) is bound by Crizotinib (Compound)
Triflupromazine (Compound) upregulates SREBF2 (Gene) and SREBF2 (Gene) regulates TNIP1 (Gene) and TNIP1 (Gene) is upregulated by Crizotinib (Compound)
Triflupromazine (Compound) upregulates MVD (Gene) and MVD (Gene) is regulated by NSDHL (Gene) and NSDHL (Gene) is upregulated by Crizotinib (Compound)
Triflupromazine (Compound) upregulates LDLR (Gene) and LDLR (Gene) regulates PTK2 (Gene) and PTK2 (Gene) is bound by Crizotinib (Compound)